STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Mr. Aeschlimann, who led STAAR's commercial expansion across Asia and the Middle East from 2002 to 2010, returns after more than a decade building and leading.

Business Wire • 14 hours ago

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2026

STAAR Surgical to Participate in Upcoming Investor Conferences

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Warren Foust, President and Chief Executive Officer, and Deborah Andrews, Executive Vice President and Chief Financial Officer, will participate in two investor conferences in November: Stifel 2026 Healthcare Conference Date: Tuesday, November 10, 2026 Location: New York, NY Fires.

Business Wire • Oct 27, 2026

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday, November 4, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET that same day to discuss its financial results.

Business Wire • Oct 21, 2026

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If you are a current shareholder of STAA, you can request additional information here: https://zlk.com/cases/staar-surgical-company-class-action-lawsuit-staa-3 or contact Joseph E.

PRNewsWire • Oct 21, 2026

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company's senior leadership team to capitalize on opportunities th.

Business Wire • Oct 8, 2026

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.

The Motley Fool • Sep 29, 2026

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Sep 29, 2026

Why Staar Surgical Stock Soared Today

It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.

The Motley Fool • Sep 25, 2026

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Under its buyback program, STAAR may repurchase shares in the open market, through privately ne.

Business Wire • Sep 24, 2026